Sight.ai receives CHF 40,000 from Venture Kick to scale AI-powered cellular imaging platform
28.05.2026
Sight.ai receives CHF 40,000 from Venture Kick to advance its AI-powered analytics platform for augmented cellular imaging. By replacing fragmented imaging workflows with a unified platform combining foundation models and AI agents, the startup aims to streamline biological image analysis for life-science research and pharmaceutical R&D.
 Mathieu Fréchin Co-Founder Sight.ai
|
 |
What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you?
The first real signal came from conversations with imaging-center directors and senior imaging scientists. Without any prompting, they described exactly the problem we were trying to solve: fragmented workflows and exhausted teams struggling with disconnected tools.
What stood out was how often people reacted as if we were articulating something they had already been thinking about for years. Then the conversations evolved into beta-testing discussions, NDAs with pharma companies, and benchmarking talks with major players. That’s when the signal stopped feeling anecdotal and started looking repeatable.
It also changed our mindset. We stopped operating like a scientific project and started building Sight.ai as a software company.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Sight.ai is building a unified analytics platform for augmented cellular imaging powered by AI. Today, image-based biology still relies on fragmented workflows across open-source tools, scripts, and disconnected software environments. We aim to replace that complexity with one coherent platform built for modern life-science research and industrial workflows.
The platform combines foundation models designed for biological imaging with AI agents that support different assay types and imaging modalities.
When we entered Venture Kick, we already had a published proof of concept, early patents, cloud infrastructure, an initial prototype, and letters of intent from leading research institutes. What was still missing was the commercial side: a clear go-to-market strategy, investor pipeline, and a narrative strong enough for customers and investors.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Venture Kick pushed us to focus on commercial execution much earlier. As a deeply technical team, our instinct was to keep refining the technology and assume the business side would follow later.
Instead, Venture Kick forced us to think concretely about customers, pricing, contracts, and sales ownership from the beginning. That shift helped us move from a technology-driven mindset to a customer-driven one.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding gives us the ability to focus fully on business execution over the next six months. Most of it will go toward customer traction: meeting imaging-core directors and pharma R&D teams, attending key events, and turning current NDAs and benchmarking discussions into pilot projects.
It will also support stronger commercial materials, patent filings, and dedicated founder time for investor and customer discussions. If executed well, the next stage will include scoped pilots, early paid engagements, stronger IP protection, and an MVP approaching production readiness.
The first real signal came from conversations with imaging-center directors and senior imaging scientists. Without any prompting, they described exactly the problem we were trying to solve: fragmented workflows and exhausted teams struggling with disconnected tools.
What stood out was how often people reacted as if we were articulating something they had already been thinking about for years. Then the conversations evolved into beta-testing discussions, NDAs with pharma companies, and benchmarking talks with major players. That’s when the signal stopped feeling anecdotal and started looking repeatable.
It also changed our mindset. We stopped operating like a scientific project and started building Sight.ai as a software company.
Can you briefly describe your project and where it stood when you entered Venture Kick?
Sight.ai is building a unified analytics platform for augmented cellular imaging powered by AI. Today, image-based biology still relies on fragmented workflows across open-source tools, scripts, and disconnected software environments. We aim to replace that complexity with one coherent platform built for modern life-science research and industrial workflows.
The platform combines foundation models designed for biological imaging with AI agents that support different assay types and imaging modalities.
When we entered Venture Kick, we already had a published proof of concept, early patents, cloud infrastructure, an initial prototype, and letters of intent from leading research institutes. What was still missing was the commercial side: a clear go-to-market strategy, investor pipeline, and a narrative strong enough for customers and investors.
How has the direction of your product/service/product strategy changed since working with the Venture Kick Team?
Venture Kick pushed us to focus on commercial execution much earlier. As a deeply technical team, our instinct was to keep refining the technology and assume the business side would follow later.
Instead, Venture Kick forced us to think concretely about customers, pricing, contracts, and sales ownership from the beginning. That shift helped us move from a technology-driven mindset to a customer-driven one.
How will the Stage 2 funding help you advance your project concretely?
Stage 2 funding gives us the ability to focus fully on business execution over the next six months. Most of it will go toward customer traction: meeting imaging-core directors and pharma R&D teams, attending key events, and turning current NDAs and benchmarking discussions into pilot projects.
It will also support stronger commercial materials, patent filings, and dedicated founder time for investor and customer discussions. If executed well, the next stage will include scoped pilots, early paid engagements, stronger IP protection, and an MVP approaching production readiness.